GlassScriptPhysician profile
Neil Michael S Estrella
NPI 1669401030
$1,662.32
in general payments reported to CMS, 2019-2025
26 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.44 · 2020: $58.21 · 2021: $173 · 2022: $297 · 2023: $132 · 2024: $382 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.77 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $266.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $174.88 | 2022-2025 | |
| Novo Nordisk INC | $90.04 | 2021-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $72.59 | 2021-2022 | |
| Exact Sciences Corporation | $61.80 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $61.63 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $51.06 | 2021-2025 | Arexvy, Shingrix |
| Eyevance Pharmaceuticals LLC | $50.04 | 2020-2022 | |
| Pfizer INC. | $49.93 | 2025 | |
| Sanofi-Aventis U.S. LLC | $47.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $42.96 | 2019-2024 | |
| Amarin Pharma, INC. | $29.11 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.26 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $22.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.02 | 2024 | Dificid, Lagevrio |
| Abbott Laboratories | $17.13 | 2024 | Freestyle Libre |
| Bigfoot Biomedical INC | $16.96 | 2021 | |
| Daiichi Sankyo INC. | $16.56 | 2024 | Injectafer |
| Radius Health, INC. | $15.79 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2023 | |
| Ibsa Pharma INC. | $14.87 | 2024 | Tirosint, Licart |
| Smith+Nephew, INC. | $14.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.56 | 2021 | |
| Janssen Biotech, INC. | $14.44 | 2019 | |
| Mylan Specialty L.P. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Michael Estrella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.